These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26552668)

  • 1. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.
    Derenzini E; Stefoni V; Pellegrini C; Gandolfi L; Broccoli A; Casadei B; Quirini F; Argnani L; Tonialini L; Zinzani PL
    BMC Cancer; 2015 Nov; 15():879. PubMed ID: 26552668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.
    Derenzini E; Fina MP; Stefoni V; Pellegrini C; Venturini F; Broccoli A; Gandolfi L; Pileri S; Fanti S; Lopci E; Castellucci P; Agostinelli C; Baccarani M; Zinzani PL
    Ann Oncol; 2010 Jun; 21(6):1173-1178. PubMed ID: 19861578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
    Gianni AM; Bregni M; Siena S; Brambilla C; Di Nicola M; Lombardi F; Gandola L; Tarella C; Pileri A; Ravagnani F; Valagussa P; Bonadonna G
    N Engl J Med; 1997 May; 336(18):1290-7. PubMed ID: 9113932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
    De Sanctis V; Finolezzi E; Osti MF; Grapulin L; Alfò M; Pescarmona E; Berardi F; Natalino F; Moleti ML; Di Rocco A; Enrici RM; Foà R; Martelli M
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1154-60. PubMed ID: 18472357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.
    Zinzani PL; Martelli M; Bendandi M; De Renzo A; Zaccaria A; Pavone E; Bocchia M; Falini B; Gobbi M; Gherlinzoni F; Stefoni V; Tani M; Tura S
    Haematologica; 2001 Feb; 86(2):187-91. PubMed ID: 11224489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
    Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
    Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
    Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
    Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
    Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
    Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
    Mazzarotto R; Boso C; Vianello F; Aversa MS; Chiarion-Sileni V; Trentin L; Zambello R; Muzzio PC; Fiore D; Sotti G
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):823-9. PubMed ID: 17379431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse.
    Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A
    Haematologica; 1990; 75(2):149-54. PubMed ID: 1694155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma.
    Santana VM; Abromowitch M; Sandlund JT; Behm FG; Ayers GD; Roberson PK; Pui CH
    Leukemia; 1993 Feb; 7(2):187-91. PubMed ID: 7678878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
    Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
    Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.
    Morimoto A; Shimazaki C; Takahashi S; Yoshikawa K; Nishimura R; Wakita H; Kobayashi Y; Kanegane H; Tojo A; Imamura T; Imashuku S;
    Int J Hematol; 2013 Jan; 97(1):103-8. PubMed ID: 23243004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.